Analysts are on the Bearish side about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) this week.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo
Investors sentiment increased to 1.43 in 2019 Q1. Its up 0.35, from 1.08 in 2018Q4. It increased, as 23 investors sold Sarepta Therapeutics, Inc. shares while 88 reduced holdings. 57 funds opened positions while 102 raised stakes. 74.26 million shares or 13.02% more from 65.70 million shares in 2018Q4 were reported.
Axa invested 0.04% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Mark Sheptoff Planning Lc has 100 shares. Oppenheimer Communication Inc invested 0.03% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). United Fincl Advisers Ltd Liability stated it has 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Highline Capital Mgmt Ltd Partnership has invested 3.27% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Polar Cap Llp holds 0.25% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 229,365 shares. Bnp Paribas Asset Mngmt Holdings Sa reported 92,861 shares. Oakbrook Investments Ltd Liability Co has invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Fuller And Thaler Asset Management reported 0.17% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). New Jersey Better Educational Savings Trust accumulated 2,000 shares or 0.32% of the stock. Adage Capital Prtn Group Ltd Limited Liability Company owns 1.65 million shares or 0.49% of their US portfolio. Voya Invest Mgmt Ltd invested in 31,970 shares or 0.01% of the stock. 7,914 are held by Jgp Glob Gestao De Recursos Ltda. Fisher Asset Mngmt Ltd Co holds 0% or 24,598 shares in its portfolio. Deutsche National Bank & Trust Ag has 1.04 million shares for 0.07% of their portfolio.

Since August 12, 2019, it had 2 insider buys, and 0 sales for $2.16 million activity. $2.00M worth of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) was bought by INGRAM DOUGLAS S on Monday, August 12.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 15 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sarepta Therapeutics has $270 highest and $16500 lowest target. $203.56’s average target is 66.89% above currents $121.97 stock price. Sarepta Therapeutics had 33 analyst reports since February 19, 2019 according to SRatingsIntel. The firm earned “Buy” rating on Friday, March 8 by H.C. Wainwright. The firm has “Buy” rating by Needham given on Monday, March 25. Nomura maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Thursday, February 28 with “Buy” rating. RBC Capital Markets maintained the stock with “Buy” rating in Thursday, February 28 report. As per Wednesday, February 27, the company rating was maintained by Piper Jaffray. Janney Capital maintained the shares of SRPT in report on Thursday, February 28 with “Buy” rating. The firm has “Overweight” rating given on Monday, March 4 by Morgan Stanley. As per Tuesday, June 25, the company rating was maintained by Cantor Fitzgerald. The stock has “Buy” rating by H.C. Wainwright on Tuesday, February 19. The firm has “Buy” rating given on Thursday, February 28 by Citigroup. Below is a list of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) latest ratings and price target changes.

09/07/2019 Broker: Inc. – Common Stock Rating: Morgan Stanley New Target: $165.0000 220.0000
01/07/2019 Broker: Inc. – Common Stock Rating: Rbc Capital New Target: $188.0000 220.0000
25/06/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $231 Maintain
21/06/2019 Broker: Piper Jaffray Rating: Buy New Target: $208 Maintain
16/05/2019 Broker: Inc. – Common Stock Rating: Citigroup New Target: $201.0000 190.0000
09/05/2019 Broker: Inc. – Common Stock Rating: Rbc Capital New Target: $191.0000 188.0000
26/04/2019 Broker: BidaskScore Rating: Hold Upgrade
12/04/2019 Broker: Evercore Rating: Outperform New Target: $175 Initiates Coverage On
26/03/2019 Broker: Citigroup Rating: Buy New Target: $201 Maintain
25/03/2019 Broker: J.P. Morgan Rating: Buy Maintain

The stock decreased 1.31% or $1.62 during the last trading session, reaching $121.97. About 962,745 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 29.09% since August 15, 2018 and is uptrending. It has outperformed by 29.09% the S&P500.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $9.07 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Nasdaq.com which released: “Is Sarepta Therapeutics (SRPT) Stock Outpacing Its Medical Peers This Year? – Nasdaq” on July 18, 2019, also Nasdaq.com with their article: “Notable Tuesday Option Activity: TEAM, UGI, SRPT – Nasdaq” published on April 02, 2019, Seekingalpha.com published: “Sell Sarepta Into PROMOVI Results – Seeking Alpha” on November 26, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Seekingalpha.com and their article: “Sarepta: When You Sell Too Early And Want Back In – Seeking Alpha” published on June 25, 2019 as well as Nasdaq.com‘s news article titled: “Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval – Nasdaq” with publication date: August 08, 2019.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.